Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data In Difficult-To-Treat Plaque Psoriasis With Proven Durability Through 2-Years, Affirming Its Use As A Powerful First Line Systemic Therapy

Oct 2 (Reuters) - Johnson & Johnson JNJ.N:

• JOHNSON & JOHNSON ANNOUNCES NEW ICOTYDE® (ICOTROKINRA) DATA IN DIFFICULT-TO-TREAT PLAQUE PSORIASIS WITH PROVEN DURABILITY THROUGH 2-YEARS, AFFIRMING ITS USE AS A POWERFUL FIRST LINE SYSTEMIC THERAPY~

• J&J - 60% SCALP PSORIASIS, 89% GENITAL PSORIASIS PATIENTS ACHIEVE COMPLETE CLEARANCE AT WEEK 112

• J&J - SAFETY FINDINGS THROUGH WEEK 112 CONSISTENT WITH ICOTYDE PROFILE, NO NEW SAFETY SIGNALS

• J&J - ICOTYDE-TREATED PATIENTS SHOW 70% CLEAR OR ALMOST CLEAR SKIN AT WEEK 112

Further company coverage: JNJ.N